The effect of an oral nutritional supplement enriched with fish oil on weight-loss in patients with pancreatic cancer

British Journal of Cancer

Volumn 81, Issue 1, 1999, Pages 80-86

  Barber, M D ^a   Ross, J A ^a   Voss, A C ^b   Tisdale, M J ^c   Fearon, K C H ^a  

^a ROYAL INFIRMARY OF EDINBURGH   (United Kingdom)

^b ABBOTT LABORATORIES   (United States)

^c ASTON UNIVERSITY   (United Kingdom)

Author keywords

Cachexia; Docosahexaenoic acid; Eicosapentaenoic acid; Fish oil; Nutritional supplementation; Pancreatic cancer

Indexed keywords

FISH OIL; ICOSAPENTAENOIC ACID;

ADULT; AGED; ARTICLE; BODY COMPOSITION; CACHEXIA; CLINICAL ARTICLE; CLINICAL TRIAL; DIET SUPPLEMENTATION; ENERGY EXPENDITURE; FEMALE; FOOD INTAKE; HUMAN; LEAN BODY WEIGHT; MALE; PANCREAS ADENOCARCINOMA; PANCREAS CANCER; PRIORITY JOURNAL; STEATORRHEA; WEIGHT GAIN;

ADENOCARCINOMA; ADMINISTRATION, ORAL; AGED; BODY COMPOSITION; DIETARY PROTEINS; DIETARY SUPPLEMENTS; DOCOSAHEXAENOIC ACIDS; EICOSAPENTAENOIC ACID; ENERGY INTAKE; FEMALE; FISH OILS; HUMANS; MALE; MIDDLE AGED; PANCREATIC NEOPLASMS; WEIGHT LOSS;

EID: 0032859278     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjc.6690654     Document Type: Article

References (34)

1. Ahlgren JD (1996) Epidemiology and risk factors in pancreatic cancer. Semin Oncol 23: 241-250
2. Barber MD, Wigmore SJ, Ross JA and Fearon KCH (1997) Eicosapentaenoic acid attenuates cachexia associated with advanced pancreatic cancer. Prostaglandins Leukot Essent Fatty Acids 57: 204
3. Beck SA, Smith KL and Tisdale MJ (1991) Anticachectic and antitumour effect of eicosapentaenoic acid and its effect on protein turnover. Cancer Res 51: 6089-6093
4. Cohn SH, Vartsky D, Vaswani AN, Sawitsky A, Rai K, Gartenhaus W, Yasumura S and Ellis KJ (1982) Changes in body composition of cancer patients following combined nutritional support. Nutr Cancer 4: 107-119
5. De Wys WD, Begg C, Lavin PT, Band PR, Bennett JM, Bertino JR, Cohen MH, Douglass HO, Engstrom PF, Ezdinli EZ, Horton J, Johnson GJ, Moertel CG, Oken MM, Perlia C, Rosenbaum C, Silverstein MN, Skeel RT, Sponzo RW and Tormey DC (1980) Prognostic effect of weight loss prior to chemotherapy in cancer patients. Am J Med 69: 491-497
6. Evans WK, Nixon DW, Daly JM, Ellenberg SS, Gardner L, Wolfe E, Shepherd FA, Feld R, Gralla R, Fine S, Kemeny N, Jeejecbhoy KN, Heymsfield S and Hottman FA (1987) A randomised trial of oral nutritional support versus ad lib nutritional intake during chemotherapy for advanced colorectal and non-small-cell lung cancer. J Clin Oncol 5: 113-124
7. Falconer JS, Fearon KCH, Plester CE, Ross JA and Carter DC (1994a) Cytokines, the acute-phase response, and resting energy expenditure in cachectic patients with pancreatic cancer. Ann Surg 219: 325-331
8. Falconer JS, Row JA, Fearon KCH, Hawkins RA, O'Riordain MG and Carter DC (1994b) Effect of eicosapentaenoic acid and other fatty acids on the growth in vitro of human pancreatic cancer cell lines. Br J Cancer 69: 826-832
9. Falconer JS, Fearon KCH, Ross JA, Elton R, Wigmore SJ, Garden OJ and Carter DC (1995) Acute-phase protein response and survival duration of patients with pancreatic cancer. Cancer 75: 2077-2082
10. Fearon KCH, Falconer JS, Ross JA, Carter DC, Hunter JO, Reynolds PD and Tuffnell Q (1996) An open-label phase I/II dose escalation study of the treatment of pancreatic cancer using lithium gammalinolenate. Anticancer Res 16: 867-874
11. Gogos CA, Ginopoulos P, Salsa B, Apostolidou E, Zoumbos NC and Kalfarentzos F (1998) Dietary omega-3 polyunsaturated fatty acids plus vitamin E restore immunodeficiency and prolong survival for severely ill patients with generalised malignancy. A randomised controlled trial. Cancer 82: 395-402
12. Hannan WJ, Cowan SJ, Plester CE, Fearon KCH and DeBeaux A (1995) Comparison of bio impedence spectroscopy and multi-frequency bioimpedence analysis for the assessment of extracellular and total body water in surgical patients. Clin Sci 89: 651-658
13. Heinrich PC, Castell JV and Andus T (1990) Interleukin-6 and the acute phase response. Biochem J 265: 621-636
14. Jelliffe DB (1966) The assessment of the nutritional status of the community, WHO Monograph 53. WHO: Geneva
15. Jensen MB, Hermann AP, Hessov I and Mosekilde I. (1997) Components of variance when assessing the reproducibility of body composition measurements using bio-impedence and the Hologic QDR-2000 DXA scanner. Clin Nutr 16: 61-65
16. Lai PBS, Ross JA, Fearon KCH, Anderson JD and Carter DC (1996) Cell cycle arrest and induction of apoptosis in pancreatic cancer cells exposed to eicosapentaenoic acid in vitro. Br J Cancer 74: 1375-1383
17. Leaf A and Weber PC (1988) Cardiovascular effects of n-3 fatty acids. N Engl J Med 318: 549-557
18. Loprinzi CL, Schaid DJ, Dose AM, Burnham NL and Jensen MD (1993) Body-composition changes in patients who gain weight while receiving megestrol acetate. J Clin Onc 11: 152-154
19. McMillan DC, O'Gorman P, Fearon KCH and McArdle CS (1997) A pilot study of megestrol acetate and ibuprofen in the treatment of cachexia in gastrointestinal cancer patients. Br J Cancer 76: 788-790
20. McNamara MJ, Alesander HR and Norton JA (1992) Cytokines and their role in the pathophysiology of cancer cachexia. JPEN J Parenter-Enterol Nuit 16 Suppl: 50S-55S
21. Meydani SN, Lichtenstein AH, Cornwall S, Meydani M, Goldin BR, Rasmussen H, Dinarello CA and Schaefer EJ (1993) Immunological effects of National Cholesterol Education Panel Step-2 diets with and without fish-derived n-3 fatty acid enrichment. J Clin Invest 92: 105-113
22. Moldawer LL and Copeland EM (1997) Proinflammatory cytokines, nutritional support, and the cachexia syndrome. Interactions and therapeutic options. Cancer 79: 1828-1839
23. Ovesen L, Hannibal J and Mortensen EL (1993a) The interrelationship of weight loss, dietary intake, and quality of life in ambulatory patients with cancer of the lung, breast, and ovary. Nutr Cancer 19: 159-167
24. Ovesen L, Allingstrup L, Hannibal J and Mortensen EL, Hansen OP(1993b) Effect of dietary counseling on food intake, body weight, response rate, survival, and quality of life in cancer patients undergoing chemotherapy: a prospective, randomised sludy. J Clin Oncol 11: 2043-2049
25. Perez MM, Newcomer AD, Moertel CG, Go VLW and DiMagno EP (1990) Assessment of weight loss, food intake, fat metabolism, malabsorption, and treatment of pancreatic insufficiency in pancreatic cancer. Cancer 52: 346-352
26. Shizgal HM (1990) Validation of the measurement of body composition from whole body bioelectric impedence. Infusionstherapic 17 suppl 3: 67-74
27. Simons JPFHA, Aaronson NK, Vansteenkiste JF, ten Velde GPM, Muller MI, Drenth BM, Erdkamp FLG, Cobben EGM, Schoon EJ, Smeets JBE, Schouten HC, Demedts M, Hillen HFP, Blijham GH and Wouters EFM (1996) Effects of medroxyprogesterone acetate on appetite, weight, and quality of life in advanced-stage non-hormone-sensitive cancer: A placebo-controlled multicenter study. J Clin Oncol 14: 1077-1084
28. Simons JPFHA, Schols AMWJ, Hoefnagels JMJ, Westerterp KR, JF, ten Velde GPM and Wouters EFM (1998) Effects of medroxyprogesterone acetate on food intake, body composition, and resting energy expenditure in patients with advanced nonhormonc-sensitive cancer. Cancer 82: 553-560
29. Tisdale MJ (1996) Inhibition of lipolysis and muscle protein degradation by EPA in cancer cachexia. Nutrition 12 Suppl: S31-33
30. Todorov P, Cariuk P, McDevitt T, Coles B, Fearon K and Tisdale M (1996) Characterisation of a cancer cachectic factor. Nature 379: 739-742
31. Wigmore SJ, Ross JA, Falconer JS, Plester CE, Tisdale MJ, Carter DC and Fearon KCH (1996) The effect of polyunsaturated fatty acids on the progress of cachexia in patients with pancreatic cancer. Nutrition 12 Suppl: S27-S30
32. Wigmore SJ, Plester CE, Richardson RA and Fearon KCH (1997a) Changes in nutritional status associated with unresectable pancreatic cancer. Br J Cancer 75: 106-109
33. Wigmore SJ, Plester CE, Ross JA and Fearon KCH (1997b) Contribution of anorexia and hypermetabolism to weight loss in anieteric patients with pancreatic cancer. Br J Surg 84: 196-197
34. Wigmore SJ, Fearon KCH, Maingay JP and Ross JA (1997c) Down-regulation of the acute-phase response in patients with pancreatic cancer cachexia receiving oral eicosapentaenoic acid is mediated via suppression of interleukin-6. Clin Sci 92: 215-221